Moreover, a retrospective study using electronic databases of four Israeli cancer centers showed that pembrolizumab monotherapy and combination therapy with pembrolizumab and chemotherapy provided similar OS in patients with high PD-L1 expression after propensity score matching, and a significantly longer median OS was observed only in female patients who received the combination therapy [11]. The gene discussed is CD274; the disease is cancer.